Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Corporate Investor Presentation

Rigel Corporate Investor Presentation

Date	Title
03/26/19	Rigel Welcomes Jane Wasman to Board of Directors Peter S. Ringrose, Ph.D. Retires from Board Position SOUTH SAN FRANCISCO, Calif. , March 26, 2019 /PRNewswire/ -- Rigel Pharmaceuticals , Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of
02/28/19	Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Fourth quarter total revenues of $37.9 million; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million; full year net product sales of $13.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Feb.
02/21/19	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28 , 2019. Rigel senior management will follow the announcement

Stock Quote

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume
Data as of

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site

Investors

Investors

Corporate Profile

Corporate Investor Presentation

Stock Quote

Stock Chart

E-mail Alerts